AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.98
-0.02 (-0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.00
Open4.00
Bid3.70 x 3100
Ask5.92 x 1800
Day's Range3.91 - 4.07
52 Week Range3.31 - 15.00
Volume442,892
Avg. Volume808,106
Market Cap179.933M
Beta (3Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire6 days ago

    Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin

    -- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment.

  • GlobeNewswire20 days ago

    Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial.

  • GlobeNewswirelast month

    Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant gram-negative ...

  • GlobeNewswirelast month

    Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    --Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT--. SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing ...

  • GlobeNewswire2 months ago

    Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018-- Achaogen, Inc., a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today highlighted ...

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Northeast, Hurco Companies, PGT, Bassett Furniture Industries, Insys Therapeutics, and Achaogen — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northeast ...

  • GlobeNewswire2 months ago

    Achaogen to Present at the Wedbush PacGrow Healthcare Conference

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference taking place August 14 to 15, 2018 in New York City. Achaogen management will present at 8:00 a.m. Eastern Time on Tuesday, August 14th, 2018. A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com.

  • GlobeNewswire3 months ago

    Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    --ZEMDRI, approved in the U.S. for the treatment of adults with complicated urinary tract infections--. --Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first ...

  • ACCESSWIRE3 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...

  • GlobeNewswire3 months ago

    CMS Grants New Technology Add-on Payment to ZEMDRI™ (plazomicin)

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ZEMDRI when administered in the hospital inpatient setting. In the final rule concerning Hospital Inpatient Prospective Payment Systems and Fiscal Year 2019 Rates, CMS stated that “ZEMDRI offers a substantial clinical improvement for patients who have limited or no alternative treatment options because it is a new antibiotic that offers a treatment option for a patient population unresponsive to currently available treatments” and that “ZEMDRI meets all the criteria for approval of new technology add-on payments.” Additional information on the final rule and its discussion of NTAP and ZEMDRI can be found online at: HIPPS.

  • GlobeNewswire3 months ago

    Achaogen Announces Strategic Update to Align Operations with Commercial and Clinical Development Priorities

    Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced a strategic update and corporate restructuring to focus resources on the successful commercialization of ZEMDRITM in the United States, the Marketing Authorization Application (MAA) filing for ZEMDRI in the European Union, and continued development of the C-Scape program. Consistent with the Company’s mission, Achaogen’s research and development efforts will focus on C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, and new aminoglycoside antibiotics, both of which have non-dilutive funding commitments.

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Achaogen and Avinger

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen

    NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...

  • ACCESSWIRE5 months ago

    Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).

  • ACCESSWIRE6 months ago

    Blog Exposure - Lexicon Pharma’s New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LXRX as the Company's latest news hit the wire. On May 04, 2018, the Company announced that new XERMELO® (telotristat ethyl) data from the randomized, double-blind, placebo-controlled Phase-3 TELESTAR study were published in March issue of Clinical Therapeutics. The publication provides the first report of the effects of XERMELO® on changes in weight in patients with neuroendocrine tumors (NETs) and carcinoid syndrome that participated in the Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome (TELESTAR) study.

  • ACCESSWIRE6 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:30 AM Eastern Time. To listen ...